BB-K 8, a new semisynthetic aminoglycoside antibiotic.
D000613:Aminobutyrates / Q000008:administration & dosage / Q000097:blood / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity / Q000652:urine; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004352:Drug Resistance, Microbial; D004927:Escherichia coli Infections / Q000188:drug therapy; D007275:Injections, Intravenous; D007612:Kanamycin / Q000008:administration & dosage / Q000097:blood / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity / Q000652:urine; D007928:Lethal Dose 50; D051379:Mice; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy; D051381:Rats; D013203:Staphylococcal Infections / Q000188:drug therapy
D000613:Aminobutyrates; D000900:Anti-Bacterial Agents; D007612:Kanamycin